Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society
| Autor: | Catherine Lambert, D Selleslag, J Depaus, Yves Beguin, Ann Janssens |
|---|---|
| Přispěvatelé: | UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty diagnosis Treatment goals 03 medical and health sciences 0302 clinical medicine Belgium immune system diseases Internal medicine hemic and lymphatic diseases medicine Humans Short course 030212 general & internal medicine Intensive care medicine Pregnancy Purpura Thrombocytopenic Idiopathic Hematology treatment business.industry Immunoglobulins Intravenous General Medicine medicine.disease bleeding Immune thrombocytopenia Intravenous Immunoglobulins 030220 oncology & carcinogenesis Rituximab pregnancy business Primary immune thrombocytopenia Prolonged treatment medicine.drug |
| Zdroj: | Acta clinica Belgica, Vol. 77, no. 2, p. 470-483 (2021) |
| Popis: | The Belgian Hematology Society (BHS) updated the 2013 guidelines for diagnosis and treatment of primary immune thrombocytopenia (ITP) [1]. As knowledge about ITP pathophysiology is increasing, the mode of action of old therapies is better understood and novel drugs are introduced to target more specific pathways.Corticosteroids with or without intravenous immunoglobulins (IgIV) remain the first-line treatment. According to the updated international guidelines a short course of corticosteroids rather than a prolonged treatment has to be recommended. The same guidelines stress that consequent therapies as thrombopoietic agents (TPO-RAs) and rituximab should be available independent of duration of ITP.Although the majority of recommendations is based on very low-quality evidence, it is strongly advised to individualize the ITP management taking patient values. and preferences in account. The main treatment goal in all ITP patients must be to maintain a safe platelet count to prevent or stop bleeding with a minimum of toxicity and not to normalize the platelet count. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|